New diabetes shot aims to beat semaglutide in early trial
NCT ID NCT07187856
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 2 study tests an experimental drug called PG-102, given as a weekly injection, in 80 adults with type 2 diabetes. Participants will receive either PG-102, a placebo, or the approved drug semaglutide for 24 weeks. The main goal is to see how well PG-102 lowers blood sugar (HbA1c) compared to placebo, with additional checks on weight changes and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PG-102 (an experimental drug injected weekly)
- What this could lead to
- If successful, PG-102 could offer a new weekly injection option to help control blood sugar and possibly reduce weight in people with type 2 diabetes.
- What could go wrong
- This is an early Phase 2 trial with only 80 participants, so results may not apply to everyone. The drug may not work better than existing treatments like semaglutide, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emeritus Research
Camberwell, Victoria, 3124, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Student pharmacists may hold the key to better diabetes control in older asian adults
- Can a blood vessel drug beat aspirin at preventing heart attacks in diabetes?
- New Dual-Action drug aims to tackle fatty liver where semaglutide falls short
- Can a 12-Week exercise program boost brain and body health in older adults with diabetes?
- Diabetes drugs may shield against severe pneumonia outcomes
- Saliva test could spot hidden links between diabetes and gum disease